Stocktoria
Omada Health, Inc. OMDA
Omada Health, Inc. (OMDA) earns a Piotroski F-score of 6/9 (mixed financial health), with an Altman Z″ in the grey zone. It does not currently pay a dividend. FY2025 revenue was $260.2M at a -4.9% net margin.
Beneish M-score: -2.61 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Services · percentile among 982 companies
Percentile vs other Services companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 6/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · grey zone
| Component | Value |
|---|---|
| Working capital / assets | 0.646 |
| Retained earnings / assets | -1.496 |
| EBIT / assets | -0.039 |
| Equity / liabilities | 3.033 |
Sector peers · similar-size Services companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| OMDA | Omada Health, Inc. | 6/9 | 2.28 | — | +53.2% |
| TALK | Talkspace, Inc. | 6/9 | 5.28 | 112.2 | +22% |
| DCGO | DocGo Inc. | 4/9 | -4.05 | — | -47.7% |
| SRTA | Strata Critical Medical, Inc. | 4/9 | 6.54 | 11.1 | +34.3% |
| WGS | GeneDx Holdings Corp. | 6/9 | -5.22 | — | +40% |
| VSEE | VSEE HEALTH, INC. | 3/9 | -16.83 | — | +40.3% |
| EUDA | EUDA Health Holdings Ltd | 5/9 | — | — | — |
About Omada Health, Inc.
Omada Health, Inc., together with its subsidiary, Physera, Inc., provides a range of virtual care programs in the United States. The company offers cardiometabolic programs for prediabetes, diabetes, and hypertension; a physical therapy program to address musculoskeletal conditions; other support programs for members taking glucagon-like peptide-1 agonists in its cardiometabolic program; and weight management programs, as well as various behavioral health support programs. It also delivers virtual care. The company offers its programs for employers, health plans and systems, and pharmacy benefits managers through its direct sales force and channel partners. The company was incorporated in 2011 and is headquartered in South San Francisco, California.
FAQ
Is OMDA financially healthy?
Omada Health, Inc.'s Piotroski F-score is 6/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the grey zone.
Does OMDA pay a dividend?
No, Omada Health, Inc. does not currently pay a dividend.
How profitable is OMDA?
In FY2025, Omada Health, Inc. had a net margin of -4.9% and a return on equity of -5.6%.
What is the analyst price target for OMDA?
The average Wall-Street price target for Omada Health, Inc. is $22.92, about 3.9% below the recent price, from 12 analysts.
Is OMDA a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Omada Health, Inc.: a Piotroski F-score of 6/9, an Altman Z″ in the grey zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.